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Background: Fragile X syndrome (FXS) is an inherited neurodevelopmental condition characterised by behavioural,
learning disabilities, phisical and neurological symptoms. In addition, an important degree of comorbidity with
autism is also present. Considered a rare disorder affecting both genders, it first becomes apparent during
childhood with displays of language delay and behavioural symptoms.
Main aim: To show whether the combination of 10 mg/kg/day of ascorbic acid (vitamin C) and 10 mg/kg/day of
α-tocopherol (vitamin E) reduces FXS symptoms among male patients ages 6 to 18 years compared to placebo
treatment, as measured on the standardized rating scales at baseline, and after 12 and 24 weeks of treatment.
Secondary aims: To assess the safety of the treatment. To describe behavioural and cognitive changes revealed
by the Developmental Behaviour Checklist Short Form (DBC-P24) and the Wechsler Intelligence Scale for
Children–Revised. To describe metabolic changes revealed by blood analysis. To measure treatment impact at
home and in an academic environment.
Methods/Design: A phase II randomized, double-blind pilot clinical trial. Scope: male children and adolescents
diagnosed with FXS, in accordance with a standardized molecular biology test, who met all the inclusion criteria
and none of the exclusion criteria. Instrumentation: clinical data, blood analysis, Wechsler Intelligence Scale for
Children–Revised, Conners parent and teacher rating scale scores and the DBC-P24 results will be obtained at the
baseline (t0). Follow up examinations will take place at 12 weeks (t1) and 24 weeks (t2) of treatment.
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Discussion: A limited number of clinical trials have been carried out on children with FXS, but more are necessary as
current treatment possibilities are insufficient and often provoke side effects. In the present study, we sought to
overcome possible methodological problems by conducting a phase II pilot study in order to calculate the relevant
statistical parameters and determine the safety of the proposed treatment. The results will provide evidence to improve
hyperactivity control and reduce behavioural and learning problems using ascorbic acid (vitamin C) and α-tocopherol
(vitamin E). The study protocol was approved by the Regional Government Committee for Clinical Trials in Andalusia
and the Spanish agency for drugs and health products.
Trial registration: ClinicalTrials.gov Identifier: NCT01329770 (29 March 2011)
Keywords: Antioxidants, Experimental treatment, Fragile X syndrome, Oxidative stress, TrialBackground
Fragile X syndrome (FXS) was first described by Martin
and Bell in 1943 in families with several males affected by
sex-linked mental retardation [1]. It later was identified as
the most common cause of inherited mental retardation
[2-4]. The prevalence of FXS has been estimated at 1 in
2,500 males and 1 in 4,000 females [5,6].
In addition to moderate to severe mental retardation,
individuals with FXS exhibit macroorchidism—an elon-
gated face, long ears, connective tissue dysplasia, hyper-
activity, autistic-like and stereotypical behaviours, speech
delay and increased sensory sensitivity [7,8]. Neuro-
pathological features of FXS are a long, thin, tortuous
appearance of cortical dendritic spines, increased intra-
cranial volume, enlarged ventricles, increased volume of
selective subcortical grey-matter regions and decreased
size of the posterior cerebellar vermis [9], and, in a
mouse model, altered glucose metabolism [10].
The name fragile X syndrome came into existence upon
the discovery of a fragile site in the long arm of the X
chromosome detected by cytogenetic testing in a cell cul-
ture medium deprived of folic acid [11]. The fragile X
mental retardation 1 (FMR1) gene was linked to the region
(Xq27.3), and a dynamic CGG repeat expansion mutation
was identified as the cause of the syndrome [12]. A full
mutation with more than 200 CGG repeats causes methy-
lation of FMR1 and leads to transcriptional silencing of
the gene [13]. It has been established that a normal range
of CGG repeats varies between 6 and 55, and a CGG ex-
pansion over this range is considered abnormal. An un-
stable premutation allele consists of more than 55 CGG
repeats, resulting in reduced levels of the fragile X mental
retardation 1 protein (FMRP) encoded by FMR1, despite a
larger quantity of its mRNA. This may be due to a com-
pensatory mechanism derived from a translation problem
in the premutated mRNA [14]. A late-onset neurodegen-
erative disorder that causes intention tremor, problems
with coordination and balance (cerebellar ataxia) and cog-
nitive disability has been described in males and females
older than 50 to 55 years of age who are carriers of a
premutation allele. This disorder is known as fragile Xpremutation tremor/ataxia syndrome, which is caused by
an increased level of mRNA that leads to neurotoxicity in
the brain [15].
The physiological effects of FMRP are not well under-
stood, and the mechanisms that explain the pathogenesis
of this syndrome remain unclear. FMRP is an mRNA
binding protein and it forms complexes with additional
proteins to transport target mRNA from the nucleus to
the cytoplasm in microtubule-dependent movements
that drive the complexes to the neurites in PC12 cells
stimulated by nerve growth factor [16].
There is evidence that FXS is associated with alterations
in the action of the hypothalamic-pituitary-adrenal axis
[17,18]. Recently, abnormalities in glucocorticoid secretion
were shown in people with FXS and the FXS Fmr1-knock-
out mouse model [19,20]. Also, an abnormal catecholamine
content was demonstrated in this mouse model [21].
Our previous results indicate that an excess of Rac1-
GTPase activation leads to nicotinamide adenine dinucleo-
tide phosphate (NADPH) oxidase–dependent activation
and high levels of free radical production in the Fmr1-
knockout mouse brain. Elevated oxidative stress and al-
terations in the antioxidant system, including glutathione
(GSH) decrease, are observed in the Fmr1-knockout brain
[22]. Brain redox dysregulation alters emotion-related
behaviours but leaves spatial abilities intact. Thus, a GSH
deficit affects parvalbumin immunoreactive interneuron
integrity and neuronal synchrony in a region- and time-
specific manner, leading to behavioural phenotypes related
to psychiatric disorders [23].
The central nervous system is highly sensitive to oxi-
dative stress due to its specific anatomical and physio-
logical characteristics. Neurons consume oxygen to
produce ATP to maintain intracellular gradients of dif-
ferent ions (K+, Na+, Ca2+). Neurons are postmitotic
cells that are very sensitive to oxidation. Free radicals
from oxygen and nitrogen (reactive oxygen species
(ROS) and reactive nitrogen species) are involved in
redox regulation of several protein functions, such as
glutamate transporters and neurotransmitter receptors,
leading to excitotoxicity processes in the long term.
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term cell death [24].
It is well known that redox regulation is involved in
many important cellular mechanisms in neurons, astro-
cytes and microglia, such as the activation of the mitogen-
activated protein kinase (MAPK) cascade (extracellular
signal-related kinase 1/2 (ERK1/2), c-Jun N-terminal kin-
ase 1/2, p38MAPK), Ca2+ release and the activation of
apoptotic processes [25,26]. ROS produced by mitochon-
drial proteins or membrane proteins (such as NADPH
oxidase activated by Rac1) have a role in physiological
plasticity and may be required for normal cognitive func-
tions [27]. An excess of ROS, however, may induce
harmful changes in cellular physiology, and cells can be
protected from oxidation with antioxidant processes and
detoxification, such as the activation of the glutathione
system. GSH plays a critical role as an antioxidant, enzyme
cofactor, cysteine storage form and the major redox buffer,
and it is a neuromodulator in the central nervous system.
One of its most important roles is serving as a carrier/
storage form for cysteine. Cysteine itself has neurotoxic
effects mediated by free radical generation, which in-
creases extracellular glutamate and triggers the overacti-
vation of N-methyl-D-aspartate (NMDA) receptors. It
can also serve as a neuromodulator/neurotransmitter and
binds via its γ-glutamyl moiety to NMDA receptors [28].
In addition, it is thought to exert dual (agonistic and an-
tagonistic) actions on neuronal responses mediated by
NMDA receptors in the brain. GSH also serves as an en-
dogenous nitric oxide (NO) reservoir to form S-nitroso-
glutathione (GSNO). GSNO can release NO under certain
conditions with biological effects, whereas it has a protect-
ive effect in the brain under oxidative stress conditions
[29]. In addition, it is required for cell proliferation and
neuronal differentiation [30].
GSH deficiency has been implicated in neurodegen-
erative diseases. It is a tripeptide composed of glutam-
ate, cysteine and glycine. Cysteine is the rate-limiting
substrate for the synthesis within neurons. Most neur-
onal cysteine uptake is mediated by sodium-dependent
excitatory amino acid transporter (EAAT) systems,
known as excitatory amino acid carrier 1. Previous
studies have demonstrated that EAAT is regulated by
redox status, leading to impaired function by glutam-
ate accumulation in the synaptic cleft during oxidative
stress [31].
Oxidative stress can activate genes that encode the
enzymes of antioxidant defence or transcription factors
(nuclear factor κB, activator protein 1 and nuclear
factor of activated T-cells) and many other structural
proteins. The increase of Ca2+ in neurons can activate
other enzymes, including protein kinase C (PKC), phos-
phatase, phospholipase, neuronal nitric oxide synthase
and xanthine oxidase [26,27].The normalization of oxidative stress can represent a
new experimental target in the treatment of disorders
caused by excessive production of free radicals. Oxidative
stress has been found in neurological disorders, including
epilepsy, Parkinson’s disease, Down syndrome, Rett syn-
drome, autism and Alzheimer’s disease [32]. It has been
demonstrated that neuronal damage due to oxidative
stress and/or hyperadrenergic states can be prevented by
treatment with free radical scavengers or specific com-
pounds that act to prevent free radical production. It has
been shown that neuroprotective therapy prevents neuronal
damage in neurodegenerative diseases such as Parkinson’s
disease and Alzheimer’s disease [33,34]. Nutrient deficien-
cies are common in attention-deficit/hyperactivity disorder
(ADHD). Supplementing the diet with minerals, vitamins,
essential fatty acids omega-3 and omega-6, bioflavonoids
and phosphatidylserine have been demonstrated to im-
prove ADHD symptoms [35].
Currently, the pharmacological treatment used for
FXS has limited effects on the symptoms observed in pa-
tients. Stimulants of the central nervous system, such as
methylphenidate, are used to treat hyperactivity, and
antipsychotic drugs, such as risperidone, are used to
treat aggressive behaviour. Several drugs have been used
to treat anxiety, such as alprazolam and lorazepam. Pa-
tients with epilepsy have been prescribed anticonvulsive
drugs. In general, a drug or drug combinations are used
to treat clinical symptoms, and there are no specific
drugs that prevent the appearance of the disorders [36].
High-dose vitamin E supplementation may improve in-
sulin action and decrease plasma fasting insulin and glu-
cose levels by decreasing cellular oxidative stress, altering
membrane properties and decreasing inflammatory activ-
ity [37]. Increased vitamin E intake may enhance the en-
dogenous cellular antioxidant defence system and reduce
levels of ROS that are produced by the mitochondria.
Vitamin E can also act at the cellular level independently
of its antioxidant activity and may potentially contribute
to improved insulin action through the inhibition of PKC
[38], the decrease of intracellular levels of diacylglycerol
[39] and the activation of insulin substrate protein 1 [40].
Vitamin E has also been used in children. Most clinical
data are available for α-tocopherol or tocopherol esters,
such as α-tocopheryl acetate. The use of vitamin E to treat
diseases such as abetalipoproteinaemia [41], cystic fibrosis
[42-44], β-thalassaemia, sickle cell anaemia [45], inborn
errors of metabolism [46], epidermolysis bullosa [47], glucose-
6-phosphate dehydrogenase deficiency [48] and focal seg-
mental glomerulosclerosis is well documented [49]. In many
studies, the rationale for dosage has not been stated and
dosing regimens have not been evaluated systematically.
This is demonstrated by cystic fibrosis studies in children.
Doses have differed among the studies: 5.5 to 47.4 IU/kg/
day, 5 to 10 mg/kg/day and 50 to 100 IU/day [50,51].
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dren; most available clinical data are for ascorbic acid or
antioxidant combinations. The use of vitamin C is well
documented in diseases such as aphthous stomatitis
[52], infant burns [53], hyperlipidaemia and arterioscler-
osis [54]. An oral dosage of 2,000 mg/m2/day of ascor-
bate may modulate the generation of ROS and augment
neutrophil apoptosis, which could prevent neutrophil-
mediated inflammation in children. A 12-month high-
dose (30 mg/kg/day) trial of oral ascorbic acid was
reported to be safe and well tolerated in children ages 2
to 16 years [55]. Vitamin C was also administered, as it
enhances regeneration of oxidized vitamin E. Kinetic
analysis and studies of vitamin E regeneration in a
protein-denaturing system revealed that ascorbate re-
generates vitamin E by a nonenzymatic mechanism,
whereas glutathione regenerates vitamin E enzymati-
cally. It has been suggested that significant interaction
occurs between water- and lipid-soluble molecules at
the membrane–cytosol interface and that vitamin C
may function in vivo to repair membrane-bound oxi-
dized vitamin E [56].Methods/Design
We designed a clinical trial to evaluate the effects of
an antioxidant combination of ascorbic acid and α-
tocopherol on the clinical condition of patients with
FXS. The study includes patients from age 6 years up to
age 18 with diagnosed FXS. This age limit was chosen
because it is within this age range that a decline in
hyperactivity and behavioural symptoms may occur.
The minimum duration of treatment and follow-up for
these patients is to be 6 months. The symptoms most
easily measured are the presence and severity of behav-
ioural abnormalities.
Here we present a new therapeutic approach to FXS
that is based on the hypothesis that an increase in free
radical production and a deficit in vitamins are involved
in the pathology and that this often provokes severe co-
morbidity. Moreover, we take into account that current
treatment protocols are frequently ineffective among
young children and carry a risk for important potential
side effects. Thus, we propose the following goals. (1)
Our main goal is to test whether the combination of 10
mg/kg/day α-tocopherol and 10 mg/kg/day ascorbic
acid reduces hyperactivity and behaviour abnormalities,
improving cognition among patients between 6 and 18
years of age compared to placebo treatment. (2) Sec-
ondary goals are to assess the safety of the treatment, in
terms of adverse events; to describe metabolic changes
resulting from the treatment, as revealed by blood test
results; and to measure the impact of this treatment on
the quality of family and social life.Design
Type of clinical trial
This is a phase II, double-blind, randomized clinical study.
It began in December 2011 and is currently in progress.
Recruitment of patients
The patients recruited will be those diagnosed with FXS
according to molecular biology test who have currently
presenting symptoms. Paediatric neurologists from the
Andalusian region of Spain will be informed about the
clinical trial so that patients can be referred to clinics
where the study will be carried out. In order to maintain
double-blind conditions, the doctors responsible for pa-
tient evaluation will be derived from the pharmacy de-
partment to be allocated to one of the two study groups
according to a randomization program. Informed con-
sent will be obtained from the patients’ parents or
guardians (see Figure 1).
Study subjects
Male patients ages 6 to 18 years with a diagnosis of FXS
and clinical and behavioural symptoms of the disorder
will be recruited.
Selection criteria
Criteria for inclusion
 Male patients ages 6 to 18 years: This is the age range
during which the natural course of the condition is
most exacerbated. Before the age of 6 years,
hyperactivity may not yet have appeared. After age
18 years, behavioural symptoms tend to stabilize.
 Informed consent of the child’s parents or guardians
and reasoned agreement with patients older than
12 years of age.
 Molecular diagnosis of FXS according to molecular
biology criteria of having more than 200 CGG
repeats and hypermethylation of the promoter
region of the FMR1 gene.
 Hyperactivity and behavioural symptoms of the
disorder.
Criteria for exclusion
 Severe neurological conditions not clinically
controlled.
 Unrelated neurological disorders.
 Allergy to formula components (or excipient used).
Randomization criteria
 Criteria set out above (age, diagnosis, consent).
 Current pharmacological treatment for behavioural
symptoms.
Figure 1 Clinical trial flowchart.
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Patients who fulfil these criteria will be included, ran-
domly, in one of the two groups.
Randomization, blinding and assignment to treatment group
Randomization is centralized and performed immediately
after the inclusion of an eligible patient. A software pro-
gram will be used to ensure that allocation concealment is
maintained within the pharmacy department at the Virgen
de las Nieves Hospital (Granada). The randomization code
will be kept concealed by the pharmacy department re-
sponsible for dispensing the corresponding medication.
Randomization by blocks and stratification for confusion
factors (age and concomitant medication) was performed
to reduce bias (see Figure 2). Randomization to either thetreatment group or the placebo group will be performed
only when a patient with FXS is considered eligible to re-
ceive the medication included in this study and an in-
formed consent form is signed by the caregiver.
Instrumentation
The clinical data and the results of the Wechsler
Intelligence Scale for Children–Revised (WISC-R), the
Conners Parent Rating Scale–Revised: Long Form (CPRS-
R) [57], the Conners Teacher Rating Scale–Revised: Long
Form (CTRS-R) and the Developmental Behaviour Check-
list Short Form (DBC-P24) will be assessed at the baseline
of the clinical condition (t0), at an intermediate time point
after 12 weeks of treatment (t1) and at the end of the ex-
perimental period after 24 weeks of treatment (t2). The
parents and/or guardians will be informed about the study
Figure 2 Randomization criteria for the trial. Randomization by blocks and stratification for confusion factors (age and concomitant
medication). T: Treated group, C: Control group.
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previously randomized medication will be provided. The
medication is to be taken at the patient’s home, and a
phone call follow-up is to be performed by the same
neuropsychologist in charge of the evaluation at 30, 60,
120 and 150 days. Blood tests will be performed at the
start (t0), intermediate time point (t1) and at the end of
the experimental period (t2) for each of the 30 patients.
The psychological impact of the treatment on the families
concerned will be measured using the Spanish version
of the Psychological General Well-Being Index–Revised
(PGWBI-R).
Evaluations
The clinical diagnosis of FXS will be confirmed, and the
Conners scale scores ascertained, so that the patient
may be included in the study. Any subsequent decrease
in the global score will be recorded (at t0, t1, t2). The
DBC-P24, the WISC-R and metabolic changes in the
blood test measurements will be recorded (at t0, t1, t2).
The PGWBI-R score will be determined at t0, t1 and t2
of the study period.
Withdrawal of individual patients
Patients may withdraw from the study at any time for
any reason and without any sanction for doing so. The
researcher-collaborator, after consulting with the princi-
pal investigator and the study coordinator, may also
interrupt the treatment program if the fact of continuing
this treatment, in his/her opinion, is prejudicial to the
patient’s welfare. If a patient withdraws or is withdrawn
from the study, follow-up at day 90 should be continued
whenever possible.
Follow-up of patients who withdraw from the study
Any patients whose treatment is withdrawn will continue
to be followed until the event in question is resolved or
until, in the researcher’s opinion, important changes in the
patient’s health state are unlikely to occur. The follow-upreports at 15, 30, 60 and 90 days will be completed for all
patients who received medication (including placebo) dur-
ing this study.
Suspension of the study
In cases where severe adverse events related to the admin-
istration of the treatment are suspected, the study shall be
interrupted and the researchers and the coordinator will
decide whether to continue or otherwise. Ultimate respon-
sibility for this decision will rest with the coordinator. The
relevant clinical research ethics committees and the
health-care authorities shall be informed of any decisions
taken to interrupt, abandon or continue the study.
Ethical criteria
Applicable regulations
The study will be carried out in accordance with the
principles of the Helsinki Declaration, specifically the
European Medicines Agency Committee for Proprietary
Medicinal Products (EMEA/CPMP) declaration on the
use of a placebo in clinical trials, and in accordance with
the guideline for good clinical practice (CPMP/ICH/135/
95, 17 July 1996), as well as local regulations.
Recruitment
The study protocol was approved by the regional clinical
trial committee, the ethics committee of the University
Regional Hospital (Malaga, Spain) and the Spanish
Agency of Medicines and Medical Devices. Implementa-
tion of the study will start after the Spanish national
health-care authorities give their formal approval. Al-
though patients are to be informed that they are free to
abandon the study at any time, we shall seek to recruit
those offering the maximum probability of remaining
within the study until its conclusion.
Informed consent for minors
After identifying candidate patients for inclusion in the
clinical trial, the children will be given an oral and
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guardians will be provided with all available information
and any complementary information they may require,
and they will be given an information sheet so that their
informed consent for the children’s participation in the
trial may be obtained. Once this form has been signed, it
should be given to the researcher when the child attends
the clinic for the baseline evaluation (t0).
Liability for injury
According to the Spanish law regarding clinical trials, an
insurance policy for civil liability must be subscribed to
cover any injuries that may arise from the conduct of
the study.
Treatment details
Dosage and administration of medication
The medication used in the trial will be administered or-
ally at the patients’ homes. The medications provided
will be tocopherol acetate 10 mg/kg/day, administered in
two daily doses, and ascorbic acid 10 mg/kg/day, admin-
istered in two daily doses.
Preparation and labelling of treatment procedures
The medications used in the trial will be prepared, labelled
and stored by the pharmacy service at the Virgen de las
Nieves Hospital (Granada, Spain). The active principles of
the treatment group will be obtained via commercially
available drugs. The placebo used will be created in the
hospital’s pharmacy department and will emulate the ex-
cipients and volume of the experimental medication. Pro-
cedures for reducing the volume of medication per pack
will be implemented in accordance with International
Conference on Harmonisation requirements. The study
coordinator will supervise all procedures applied in this
respect. Double-blinding and randomization of patients in
the two groups will be carried out by the pharmacy service
at the Virgen de las Nieves Hospital (Granada, Spain).
Other medications allowed
The patients will continue taking their usual medication
to control symptoms or associated comorbid pathologies.
Moreover, they will continue receiving any preexisting
psychological or educational therapies. In addition, they
will continue taking any medication prescribed for any
other concurrent illness prior to their entering the study.
Specific methods
Evaluation of effectiveness
The clinical evaluation of the patients will be carried out by
utilising the CPRS-R) [57] and the CTRS-R [58]. These
scales have been validated for the study of hyperactivity in
children. The Conners score is applied by means of a struc-
tured questionnaire with multiple informants (generallyparents and teachers) who assess the child’s behaviour over
a period of at least 1 month. The translation into Spanish
and its adaptation to local conditions were previously vali-
dated [59].
Measurement instruments
The Spanish version of the CPRS-R will be used. Scoring
on this scale ranges from 0 to 100 points (T-score). A T-
score of 50 or more on the CPRS-R at t0 will be consid-
ered a cutoff for the inclusion of patients in the study.
The Spanish version of the CTRS-R will be used. Scoring
on this scale ranges from 0 to 100 points.
The DBC-P24 will be used [60]. The Spanish version
of the DBC-P24 (90) was used to identify the degree of
behavioural difficulties among participants. Each behav-
ioural description is scored with a 0, 1 or 2 rating, where
0 = ‘not true as far as you know’, 1 = ‘somewhat or some-
times true’ and 2 = ‘very true or often true’. The tally
provides a total score.
Completed PGWBI-R (Spanish version) forms will be
obtained from parents at the beginning and the end of
the study in order to assess the psychological repercus-
sions of the treatment on family life. This scale reflects
subjective feelings and psychological well-being (or
otherwise) during the previous week [61].
Oxidative stress status in blood will be assessed at t0, t1
and t2 to detect metabolic changes that may be related to
the effectiveness of the treatment. Qualitative changes in
the metabolism and antioxidant levels will be evaluated.
Safety evaluation
The following evaluations will be performed before and
after the treatment:
1. Haematology: haemoglobin, haematocrit, red blood
cells, white blood cells and platelets
2. Biochemistry: creatine, blood urea nitrogen, glucose,
uric acid, sodium, potassium, calcium, phosphate,
chloride, total protein, albumin, triglycerides, total
cholesterol, high-density lipoprotein, total bilirubin,
aspartate aminotransferase (serum glutamic
oxaloacetic transaminase), alanine transaminase (ALT;
serum glutamic pyruvic transaminase), γ-glutamyl
transpeptidase, alkaline phosphatase, cAMP, glutamic
acid and pyruvic acid
3. Hypothalamic-pituitary-adrenal axis (adrenaline,
noradrenaline, dopamine, cortisol,
adrenocorticotropic hormone)
4. Other tests
a. Hormones (luteinizing hormone, follicle-stimulating
hormone, growth hormone, thyroid-stimulating
hormone and thyroid hormone)
b. Neurotransmitters (serotonin, γ-aminobutyric
acid (GABA))
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d. Vitamins (vitamins A, C and E)
e. Ceruloplasmin, albumin and transferrin
f. Minerals (selenium, zinc, copper and manganese)
g. amino acids in serum
5. Analysis of urine density, pH, protein, glucose,
ketone bodies, bilirubin, blood, nitrite, urobilinogen,
leukocytes, urinary sediment, sodium, chlorine and
potassium
The following medical parameters will be evaluated in
the enrolled patients:
1. Heart symptoms: mitral valve prolapse
2. Neurological symptoms: epilepsy
3. Motor symptoms: hypotonia, fine and gross motor
delay, stereotypes and hyperextensible finger joints
4. Morphological features: macroorchidism, scoliosis,
hyperpigmentation of the skin, otitis, strabismus and
macrocephaly
Reporting of adverse events
Any adverse events reported spontaneously by the sub-
ject or observed by the researcher or the research team
will be recorded on the form designed for this purpose.
The researcher will classify the intensity of said adverse
events in accordance with the following scale:
1. Mild: some discomfort, but not such as to interrupt
normal daily activity
2. Moderate: sufficient discomfort to reduce or notably
affect normal daily activity
3. Severe: causing incapacity to work or perform
normal daily activities
The periodicity of the event shall be classified in ac-
cordance with the following scale:
1. Single occurrence: just one event of limited duration
2. Intermittent: various episodes of an event, each of
limited duration
3. Persistent, unlimited: an event that has persisted
over time and is of indefinite duration
For each adverse event, its relation to the medication
taken (definitive, probable, possible, improbable, none), in
the researcher’s opinion, as well as any action taken as a
result, will be recorded on the data collection form. The
occurrence of an adverse event that is fatal, potentially
fatal or incapacitating, or that requires or prolongs
hospitalization, or that provokes severe congenital anom-
alies will be recorded as a ‘severe’ adverse event (SAE).
All SAEs and unexpected adverse pharmacological reac-
tions, defined as adverse events whose nature or intensityis not in accordance with any adverse event expected, will
be reported by the researcher to the study coordinator by
telephone, mail or fax as soon as is reasonably possible,
but in any case within 24 hours of occurrence.
Follow-up after occurrence of an adverse event
All adverse events will be observed until their remission
or stabilization. Depending on the circumstances, this
observation might necessitate evaluation by referral to
the patient’s general practitioner and/or specialist.
Procedures and control
Selection of subjects
Patients diagnosed with FXS will be included in a prelim-
inary ‘potential subjects’ group. Before any selection activ-
ity is undertaken, a written informed consent form, signed
and dated, is to be obtained from each parent or guardian.
The patient’s parents will be informed, before any action is
taken, of the purposes of the study, and any doubts
expressed will be answered. It must be stressed that pa-
tients have the unconditional right to withdraw from the
study at any time. They will be asked to return to the
health-care clinic to begin the study procedure.
Study periods
Entry into the study (t0): The child’s parents and/or
guardians agree to be included and sign the informed
consent to enter into the clinical active phase of the
study. The CPRS-R, CTRS-R, WSIC-R and DBC-P24 re-
sults will be assessed, taking into account that a score of
at least 50 on the CPRS-R is a prerequisite for entry into
the study. The baseline blood and urine analyses will be
carried out for included patients. The PGWBI for the
parents and guardians will be calculated.
Intermediate period (12 weeks, t1): The CPRS-R, CTRS-
R, WSIC-R and DBC-P24 scores will be calculated. The t1
blood and urine analyses will be carried out for included
patients. The PGWBI scores for the parents and guardians
will be calculated.
End of study period (24 weeks, t2): The CPRS-R,
CTRS-R, WSIC-R and also DBC-P24 are calculated. The
T2 blood and urine analyses will be carried out for pa-
tients included in the study. The PGWBI for the par-
ents/guardians will be calculated.
Data analysis
Calculation of statistical power, establishment of sample
size and safety
The sample size will be established by means of a pilot
scheme based on a phase II effectiveness trial with 30
patients monitored over the course of 6 months for a
level of significance of 0.05 and a statistical power of 0.8,
taking the least favourable case. On the basis of the
prevalence of FXS, 13 patients per group (26 in total)
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sioned to allow for a possible dropout rate of 10%, and
so the minimum sample size is to be calculated as N =
30 (15 patients per group).
General considerations
A descriptive statistical analysis will be performed using
statistics of central trend and dispersion for the quantita-
tive variables and frequency distributions for the categor-
ical variables carried out separately for the experimental
and control groups. The baseline variables will be com-
pared using these techniques. A flow diagram will be
drawn to show the sequence from the initially eligible
population to those excluded from the study (refusals,
dropouts, lost to follow-up and so forth) in accordance
with the criteria in the CONSORT guidelines.
A comparison will be made of between-group differ-
ences in the initial and final measurements for the di-
verse elements of the CPRS-R, CTRS-R and DBC-P24
using unpaired nonparametric tests. For the final within-
group comparison, paired nonparametric tests will be
used for nonparametric repeated measures with adjust-
ments for baseline imbalances and scores. The same
analysis will be performed for the index of psychological
well-being to measure the repercussions of the treatment
on family life.
The principal outcome variable (POV) will be taken as
the change in global score on the Conners scales, ad-
justed for the baseline values. A simple linear regression
model will be constructed for this POV, and the level of
significance will be set at P < 0.05. Subsequently, a mul-
tiple linear regression model will be created, including
the variable ‘Experimental/Control Group’ and adjusting
for any baseline variables that may be unbalanced. Stat-
istical adjustment will be performed by means of a
multivariate model including the variable group (experi-
mental and control) and concomitant treatment (yes or
no). The safety of the treatment will be described in
terms of the percentage of adverse effects.
Discussion
FXS is considered a rare neurodevelopmental disorder,
although different rates of prevalence have been re-
ported in current studies [2,5]. The condition is seldom
diagnosed in Spain due to ignorance of its existence and
characteristics [5]. Until very recently, FXS was recog-
nized as such only for the most severe cases, in which
there was an important degree of functional limitation
and autism very evident. Although this situation in Spain
is changing, FXS is still considered an uncommon
disease.
Few clinical trials have been carried out with children
with FXS, because, in addition to the normal difficulties
arising in this kind of study (with adults), legalconsiderations must be borne in mind due to the neces-
sity to protect minors. Nevertheless, such studies are
clearly needed, and several are already ongoing or fin-
ished (see Table 1).
FMRP is an mRNA-binding protein that is important
for mRNA transport, mRNA stabilization and translation
regulation of mRNA into protein at the synapse [69].
FMRP is also a factor in the regulation of brain oxidative
stress, so, in the absence of FMRP, there is hyperactiva-
tion of Rac1-GTPase-dependent NADPH-oxidase signal-
ling. These alterations lead to an excess of free radical
production that, in the long term, produces oxidative
stress, which is a crucial factor in the central nervous
system that disrupts neuron, astrocyte and microglia
communication [32]. Evidence of oxidative stress in FXS
is manifested by high levels of oxidised proteins, lipid
peroxidation end products, formation of carbonyls and
oxidative alteration of the glutathione system in the
brain of the Fmr1-knockout mouse model [21].
Since 1983, it has been indicated that vitamins can im-
prove FXS patients’ cognitive status. The first vitamin
used for the treatment of the FXS was folic acid. Several
publications describe the efficacy and safety of treatment
with folic acid in people with FXS [70-73].
Two double-blind trials have assessed the safety and effi-
cacy of L-acetylcarnitine (LAC) in boys with FXS and an
additional diagnosis of ADHD. Both of the trials were ran-
domized, placebo-controlled studies with a parallel-group
design. The first study included 20 patients and compared
LAC with a dose of 100 mg/kg/day versus placebo, and
the investigators found no significant difference between
them based on the WISC-R or the Bender-Gestalt tests
and Conners questionnaires completed by teachers. How-
ever, the results CPRS-R and CTRS-R questionnaires
completed by parents and teachers at school showed a sig-
nificant reduction (Hedges g effect size = −3.94, SE = 0.91)
of hyperactive behaviour at the end of the study in the
LAC-treated subjects [74]. The second study, classified by
the authors as a phase II study, involved eight centres in
three European countries. The investigators compared
LAC at doses of 20-50 mg/kg/day versus placebo in 63 pa-
tients. A statistically significant stronger reduction of
hyperactivity and improvement of social behaviour was
observed in patients treated with LAC compared with the
placebo group, based on the results from the Conners
Global Index–Parents (CGI-P) (Hedges g effect size = −
0.30; SE = 0.28) and the Vineland Adaptive Behaviour Scales
Survey Form (Hedges g effect size = 0.52 and 0.65, SE =
0.29 and 0.29). They also reported no significant side effects
in the LAC group [75].
In one phase II parallel, randomized, double-blind,
placebo-controlled clinical trial of 4 weeks’ duration, re-
searchers assessed the efficacy and safety of the ampakine
compound CX516 versus placebo in 49 patients with FXS,
Table 1 Double-blind, randomized, placebo-controlled crossover studies of treatment of children with fragile X
syndromea
Clinical trial
registration
number
Type Compound Population Target Status Promoter Results
(reported or
pending)
NCT01894958 Phase II
multicentre
NNZ-2566 Adolescent
and adult
males
NMDA antagonists Recruiting Neuren Pharmaceuticals
(USA)
Pending
NCT01725152 Phase II single
centre
Ganaxolone Adolescents
and children
GABA-A agonist Recruiting Marinus Pharmaceuticals
(USA)
Pending
NCT02126995 Phase II single
centre
Metadoxine
(MG01CI)
Adults and
adolescents
Ion pair of
pyridoxine (vitamin
6)
Not yet
recruiting
Alcobra Pharma (USA) Pending
NCT01474746 Phase II single
centre
Sertraline Children Selective serotonin
reuptake inhibitors
Recruiting University of California, Davis
(USA)
Pending
NCT01911455 Phase II and
III Multicentre
Acamprosate Adolescents
and children
NMDA receptor
modulators
Recruiting Children’s Hospital Medical
Center (Cincinnati, OH, USA)
Pending
NCT01357239 Phase II
multicentre
Mavoglurant
(AFQ056)
Adolescents
and adults
mGlur5 antagonist Terminated Novartis (Basel, Switzerland) [62]
NCT01348087
NCT01013480 Phase II
multicentre
Arbaclofen
(STX209)
Adolescents
and adults
GABA-B agonist Terminated Seaside Therapeutics (USA) [63]
[64]
NCT01053156 Phase II single
centre
Minocycline Adolescents
and children
Antibiotic Completed University of California, Davis
(USA)
[65]
NCT01015430 Phase II
multicentre
Basimglurant
(RO4917523)
Adults mGlur5 antagonist Completed Hoffmann-La Roche Pending
NCT00895752 Phase IV
single centre
Riluzole Adults Inhibitor of
glutamate release
Completed Indiana University (USA) [66]
NCT01254045 Phase II single
centre
Oxytocin Adolescents
and adults
Social brain
neuropeptides
Completed Stanford University (USA) [67]
NCT01120626 Open label Donepezil Adolescents
and children
Cholinergic drug Completed Stanford University (USA) [68]
aGABA, γ-aminobutyric acid; GABA-B, γ-aminobutyric acid; mGluR5, metabotropic glutamate receptor 5; NMDA, N-methyl-D-aspartate.
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cation. Twenty-one of the patients had an additional diag-
nosis of autism, and four had autism spectrum disorder.
The results of that study showed no significant improve-
ment in memory, the primary outcome measured, or in
secondary measurements of language, attention/executive
function, behaviour and overall functioning in CX516-
treated subjects compared to placebo. There were minimal
side effects, no significant changes in safety parameters
and no SAEs [76].
There are also enhanced, abnormal epileptiform dis-
charges consistent with an enhanced rate of clinical sei-
zures in FXS patients, as well as auditory-dependent
seizures in the mouse model. There are several studies
regarding the use of tocopherol to control seizures in
animal models and humans [77].
Excessive metabotropic glutamate receptor 5 (mGluR5)
signalling has been proposed to be responsible for the psy-
chiatric and neurological symptoms of FXS, including cog-
nitive deficits, seizures, anxiety, perseverative movements
and social deficits. It has been documented that a 50%
reduction in mGluR5 expression in the Fmr1-knockoutmouse rescued most FXS abnormalities, including altered
ocular dominance plasticity, increased density of dendritic
spines on cortical pyramidal neurons, increased basal pro-
tein synthesis in the hippocampus, exaggerated inhibitory
avoidance extinction, audiogenic seizures and accelerated
body growth. However, macroorchidism was not rescued.
The results obtained with the use of mGluR5 antagonists
in animal models of FXS further support the mGluR
theory. 2-Methyl-6-phenylethynyl pyridine hydrochloride
(MPEP) is a potent, highly selective antagonist of mGluR5
receptors. MPEP is toxic to humans, so other mGluR5 an-
tagonists, such as fenobam and mavoglurant (AFQ056),
have been studied in FXS. Fenobam was found to be safe
in a single-dose trial in 12 adults with FXS. There were im-
provements in hyperactivity and anxiety, and 50% showed
at least a 20% improvement in prepulse inhibition [78].
In a recent randomized, double-blind, two-treatment,
two-period, crossover clinical trial of 30 male FXS patients
ages 18 to 35 years, investigators examined whether a re-
ceptor subtype-selective inhibitor of mGluR5, AFQ056,
improves the behavioural symptoms of FXS. The results
indicated no significant effects of treatment on the primary
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Community Edition (ABC-C) score, at day 19 or 20 of
treatment. Surprisingly, owing to an epigenetic effect,
seven patients with full FMR1 promoter methylation and
no detectable FMR1 mRNA, as measured with the ABC-
C, improved significantly more after AFQ056 treatment
than with placebo (P < 0.001). Twenty-four of thirty pa-
tients experienced adverse events, which were mostly mild
to moderately severe fatigue or headache [79]. A pilot
add-on trial was conducted to evaluate the safety and effi-
cacy of lithium in humans with FXS. It was hypothesized
that the absence of FMRP disrupts regulation of group 1
mGluR- and mGluR5-dependent translation in dendrites.
Lithium was found to reduce mGluR-activated translation
and reverse phenotypes in the dfxr-mutant fly and fmr1-
knockout mouse. The results indicated that lithium is well
tolerated and provides functional benefits in FXS, possibly
by modifying the underlying neural defect [80].
GABAB receptor agonists such as baclofen inhibit both
presynaptic release of glutamate and postsynaptic trans-
mission and/or intracellular signalling downstream from
mGluR5. A double-blind, placebo-controlled crossover
trial of arbaclofen has been completed in multiple cen-
tres. It included more than 150 individuals with FXS
(ages 6 years and older). The preliminary safety and effi-
cacy results are positive, with improvement in the Clin-
ical Global Impression improvement scale in those with
the most severe baseline ratings, but the trial was termi-
nated in 2013 [63,64]. The GABAergic system is also
dysregulated in FXS, and GABA is a major inhibitory
neurotransmitter receptor in the brain which is involved
in anxiety, depression, epilepsy, insomnia, learning and
memory. GABA-mediated inhibition is important in the
prevention of seizures [81].
The results of an open-label riluzole clinical trial in
FXS were published recently. Glutamatergic dysregula-
tion was implicated in the pathophysiology of FXS. Rilu-
zole was hypothesized to have an inhibitory effect on
glutamate release, block excitotoxic effects of glutamate
and potentiate postsynaptic GABAA receptor function.
ERK activation is known to be delayed in humans with
FXS and in FXS-knockout animal models. Correction of
delayed ERK activation is a potential biomarker of treat-
ment response in FXS. The results of that 6-week open-
label study of six adults with FXS show that riluzole
(100 mg/day) was not associated with a significant clin-
ical improvement, despite uniform correction of periph-
eral ERK activation [66].
In another study, the use of valproic acid (VPA) was
investigated in an attempt to identify drugs capable of
restoring the activity of the FMR1 gene. VPA is a well-
known antiepileptic drug also used as a mood stabilizer
and in migraine therapy. The VPA treatment was cap-
able of producing an adaptive behaviour improvement(defined as the performance of daily activities required
for personal and social competence) due to a significant
reduction in hyperactivity [82].
Another research group conducted a 4-week, random-
ized, double-blind, placebo-controlled, crossover study
with either 3 mg/day of melatonin or placebo given to
participants for 2 weeks and then alternated for another
2 weeks. The results of this study support the efficacy
and tolerability of melatonin treatment for sleep prob-
lems in children with FXS [83].
Minocycline, a widely used antibiotic used to treat acne
and skin infections, is another promising drug that may
target FXS core symptoms. Minocycline inhibits matrix
metalloproteinase 9 (MMP-9) and reduces inflammation
in the central nervous system. MMP-9 is elevated in FXS.
When minocycline was administered to Fmr1-knockout
mice, their hippocampal neurons exhibited mature den-
dritic spines, and, behaviourally, they showed decreased
anxiety and improved exploration skills. Off-label use of
minocycline to treat 50 individuals with FXS resulted in
two-thirds of families noticing positive language and be-
havioural improvements in their children while on the
medication. The most common reported side effect was
gastrointestinal difficulty, including loss of appetite [84].
Paribello et al. reported beneficial effects on the CGI and
the Aberrant Behaviour Checklist in an open trial of mino-
cycline involving 20 patients with FXS who were 13 years
of age or older [85].
The first trial of acamprosate, a drug with putative
mGluR5 antagonism, was reported in three adults with
FXS and autism. Medical records describing open-label
treatment with acamprosate in three patients with FXS
and a comorbid diagnosis of autistic disorder were
reviewed. In all three patients, acamprosate was associated
with improved linguistic communication. Three patients
received acamprosate over a mean 21.3 weeks of treat-
ment They showed a global clinical benefit and a marked
communication improvement was unexpected and has
potential implications for the treatment of FXS [86].
In an open-label 12-week trial of aripiprazole in 12 per-
sons with FXS ages 6 to 25 years (mean age, 14.3 years)
who were free of concomitant psychoactive drugs, the
results indicated a ≥25% improvement on the Aberrant
Behaviour Checklist irritability subscale in 10 (87%) of 12
patients. Aripiprazole is generally safe and well tolerated
and is associated with significant improvements in irritable
behaviour [87].
To assess positive antioxidant effects versus placebo, a
one-way crossover study was selected due to the impos-
sibility of abolishing a carryover of treatment effect from
the first period of treatment to the next. A ‘carryover ef-
fect’ means that the observed difference between treat-
ments depends upon the order in which the treatments
were received; hence the estimated overall treatment
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a bias towards the null) [88].
Orally administered antioxidants such as tocopherol and
ascorbic acid have been used as a nutritional supplement,
and it they are considered safe even for children. Tocoph-
erol is contraindicated in cases of vitamin K deficiency
caused by malabsorption or anticoagulant therapy. The
US Food and Drug Administration’s recommended daily
dose is 10 mg/day, but the safety dose is considered to be
800 mg/day [89].
Vitamin E (α-tocopherol) is a liposoluble vitamin with a
wide therapeutic margin. In clinical and pharmacological
trials, it has been shown to have interesting properties,
participating in oxidative deamination, transamination and
decarboxylation. It also participates in the decarboxylation
of glutamic acid to GABA, from levodopamine to dopa-
mine and from 5-hydroxytrytophan to serotonin. It pre-
sents anticonvulsant properties and seems to exercise a
neuroprotective and antitoxic effect. It can be adminis-
tered to children and has been authorized for use to treat
children with alterations in character, language and behav-
iour; learning difficulties; delayed learning to walk; convul-
sive illnesses; intoxication of the central nervous system;
trembling; and Parkinson’s disease. The dosage provided
may vary widely, as renal elimination ensures that its tox-
icity is minimal [90].
A pilot study was designed to evaluate the safety of a
novel micelle formulation (CF-1) of fat-soluble nutrients
and antioxidants and to determine its efficacy in improv-
ing plasma levels of these compounds and reducing in-
flammatory markers in induced sputum. The novel CF-1
formulation safely and effectively increased plasma levels
of important fat-soluble nutrients and antioxidants. In
addition, improvements in antioxidant plasma levels
were associated with reductions in airway inflammation
in cystic fibrosis patients [91]. The effect of α-tocopherol
and ascorbic acid on ALT levels and insulin resistance
has been evaluated in children with nonalcoholic fatty
liver disease [92].
The follow-up period of 6 months in our present trial
is based on previous trials and a minimum period of im-
proving symptoms, such as behaviour and antioxidant
status. We believe that if the patient enters the study
with a Conners T-score > 50, it will be easier to identify
significant differences, with the symptoms being con-
trolled to a greater extent, and more quickly, in the ex-
perimental group than in the control group.
The reason for performing blood and urine tests in our
experimental group at t0, t1 and t2 is to corroborate the
general safety of the treatment and to improve antioxidant
blood status, as well as to reveal any alterations occurring
in these parameters as a result of the medication adminis-
tered. Nevertheless, it seems reasonable to support the re-
sults of the clinical evaluation with objective data such asblood tests. It is also important to assess the repercussions
on family life (which tend to be greatly impaired in severe
cases) of an improvement in the control of FXS symptoms
among children. The PGWBI reflects psychological well-
being (or otherwise); it is based on theories of evaluation
of the domestic environment and is an appropriate means
of determining the distortion produced by FXS within the
household. We have no doubt that a direct correlation will
be found between the children’s symptoms and psycho-
logical well-being within the family home.
The combined application of these three measurement
methods—namely, the objectification of FXS symptoms
and incapacity, the assessment of metabolic blood and
urine changes and the evaluation of stress within the
family—will enable us to reach an objective judgment of
the effectiveness of the treatment being tested.
Conclusion
Treatment for FXS continues to present important
shortcomings and further clinical trials are necessary in
this respect, especially among children showing more se-
vere symptoms.
Trial status
This trial was designed in 2010. The protocol passed
through multiple amendments. Final approval was
obtained at the end of 2010. The expected duration of the
study is 4 years. Also published at https://www.clinical
trialsregister.eu/ctr-search/trial/2009-017837-23/ES.
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